AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CHIMERIC THERAPEUTICS LTD

0.002

0.000

Volume:7.57M

Turnover:15.14K

Market Cap:8.84M

PE:-0.26

High:0.002

Open:0.002

Low:0.002

Close:0.002

52wk High:0.009

52wk Low:0.002

Shares:4.42B

Float Shares:2.91B

Volume Ratio:18.42

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:-469.35%

ROA:-22.01%

PB:4.48

PE(LYR):-0.26

Loading ...

Overview Company News Filings

BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17

Chimeric Therapeutics Ltd - Shares to Be Issued via Two Tranches at a$0.003 per Share

THOMSON REUTERS

Chimeric Therapeutics Ltd-$8.4 M Funding to Drive Chm Cdh17 and Resignation of Cmo

THOMSON REUTERS

Chimeric Therapeutics Ltd - All Figures in AUD

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Seeks Trading Halt

Chimeric Therapeutics - Seeks Trading Halt Pending Material Capital Raising Announcement

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer

Chimeric Therapeutics Ltd - Cdh17 Granted FDA Orphan Drug Designation for Gastric Cancer

THOMSON REUTERS

Chimeric Therapeutics Ltd-Company Update-Board Changes, Shareholder Feedback & Support

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax Incentive

BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily Suspended

Chimeric Therapeutics Ltd-Chm Core Nk Combination Phase 1B Trial Update

THOMSON REUTERS

Chimeric Therapeutics Ltd-Pause in Trading

THOMSON REUTERS

Chimeric Therapeutics Ltd-Response to ASX Query Letter

THOMSON REUTERS

Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%

MT Newswires Live

Chimeric Therapeutics Ltd-Chm Cdh17 Clinical Trial Update

THOMSON REUTERS

Chimeric Therapeutics Ltd-Proposed Issue of Securities - Chm

THOMSON REUTERS

Chimeric Therapeutics Ltd-Update - Proposed Issue of Securities - Chm

THOMSON REUTERS

Initial Director's Interest Notice-CHM.AX

Professor Miles Prince appointed as Non-Executive Director-CHM.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.002,"timestamp":1770959520000,"preClose":0.002,"halted":0,"volume":7570000,"delay":0,"changeRate":0,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":2907076656,"shares":4418703619,"eps":-0.007715,"marketStatus":"Market Closed","change":0,"latestTime":"02-13 16:12:00 AEDT","open":0.002,"high":0.002,"low":0.002,"amount":15140,"amplitude":0,"askPrice":0.003,"askSize":96789225,"bidPrice":0.002,"bidSize":84945513,"shortable":3,"etf":0,"ttmEps":-0.007715,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771196400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.002,"openAndCloseTimeList":[[1770937200000,1770958800000]],"volumeRatio":18.416860400992835,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":2907076656,"roa":"-22.01%","roe":"-469.35%","lyrEps":-0.007715,"volumeRatio":18.416860400992835,"shares":4418703619,"dividePrice":0,"high":0.002,"amplitude":0,"preClose":0.002,"low":0.002,"week52Low":0.002,"pbRate":"4.48","psRate":"0.70","week52High":0.009,"institutionHeld":0,"latestPrice":0.002,"committee":-0.06517,"eps":-0.007715,"divideRate":0,"volume":7570000,"delay":0,"ttmEps":-0.007715,"open":0.002,"prevYearClose":0.002,"prevWeekClose":0.002,"prevMonthClose":0.002,"prevQuarterClose":0.002,"fiveDayClose":0.002,"twentyDayClose":0.002,"sixtyDayClose":0.003,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593452594","title":"BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452594","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593452594?lang=en_us&edition=fundamental","pubTime":"2025-12-23 09:21","pubTimestamp":1766452861,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17Dec 23  - Chimeric Therapeutics Ltd CHM.AX:$8.4 M FUNDING TO DRIVE CHM CDH17 AND RESIGNATION OF CMOSHARES TO BE ISSUED VIA TWO TRANCHES AT A$0.003 PER SHAREALL FIGURES IN AUDFurther company coverage: CHM.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUE5ZHSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2593455772","title":"Chimeric Therapeutics Ltd - Shares to Be Issued via Two Tranches at a$0.003 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455772?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2593455721","title":"Chimeric Therapeutics Ltd-$8.4 M Funding to Drive Chm Cdh17 and Resignation of Cmo","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455721?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2593455706","title":"Chimeric Therapeutics Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455706?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2592187590","title":"BRIEF-Chimeric Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2592187590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592187590?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:41","pubTimestamp":1766097692,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Seeks Trading Halt Dec 19 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:SEEKS TRADING HALT PENDING MATERIAL CAPITAL RAISING ANNOUNCEMENTFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2592182095","title":"Chimeric Therapeutics - Seeks Trading Halt Pending Material Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182095?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:30","pubTimestamp":1766097050,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2589802839","title":"BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802839","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802839?lang=en_us&edition=fundamental","pubTime":"2025-12-08 08:55","pubTimestamp":1765155319,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric CancerDec 8 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:CDH17 GRANTED FDA ORPHAN DRUG DESIGNATION FOR GASTRIC CANCERFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2589806954","title":"Chimeric Therapeutics Ltd - Cdh17 Granted FDA Orphan Drug Designation for Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589806954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589806954?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:33","pubTimestamp":1765143209,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nFWN3XC0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2586278668","title":"Chimeric Therapeutics Ltd-Company Update-Board Changes, Shareholder Feedback & Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2586278668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586278668?lang=en_us&edition=fundamental","pubTime":"2025-11-28 06:27","pubTimestamp":1764282444,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nTUE9CKSNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2585431981","title":"BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431981","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585431981?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:45","pubTimestamp":1763948734,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax IncentiveNov 24 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:CHIMERIC RECEIVES $4.5M RESEARCH AND DEVELOPMENT TAX INCENTIVEALL FIGURES IN AUDFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUE9RRQCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2583584428","title":"BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily Suspended","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584428","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583584428?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:45","pubTimestamp":1762991119,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily SuspendedNov 13  - Chimeric Therapeutics Ltd CHM.AX:CHM CORE NK COMBINATION PHASE 1B TRIAL UPDATECORE-NK + VACTOSERTIB PHASE 1B TRIAL TEMPORARILY SUSPENDEDFurther company coverage: CHM.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE7ZJZHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2583584342","title":"Chimeric Therapeutics Ltd-Chm Core Nk Combination Phase 1B Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583584342?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:21","pubTimestamp":1762989713,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE7ZJZHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2583581245","title":"Chimeric Therapeutics Ltd-Pause in Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581245?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:09","pubTimestamp":1762988989,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE8YPYFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2581089614","title":"Chimeric Therapeutics Ltd-Response to ASX Query Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2581089614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581089614?lang=en_us&edition=fundamental","pubTime":"2025-11-06 07:47","pubTimestamp":1762386469,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE7Z40VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2556877445","title":"Chimeric Therapeutics Says Study for Treatment Candidate for Tumors Advances to Second Dosing Level, Shares Fall 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556877445","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556877445?lang=en_us&edition=fundamental","pubTime":"2025-08-04 12:53","pubTimestamp":1754283189,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics  said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.Its shares fell 14% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","CHM.AU","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2556873782","title":"Chimeric Therapeutics Ltd-Chm Cdh17 Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2556873782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556873782?lang=en_us&edition=fundamental","pubTime":"2025-08-04 06:58","pubTimestamp":1754261884,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250803:nTUE7LT3GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2554725617","title":"Chimeric Therapeutics Ltd-Proposed Issue of Securities - Chm","url":"https://stock-news.laohu8.com/highlight/detail?id=2554725617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554725617?lang=en_us&edition=fundamental","pubTime":"2025-07-28 14:57","pubTimestamp":1753685824,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUECDKT6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2553225188","title":"Chimeric Therapeutics Ltd-Update - Proposed Issue of Securities - Chm","url":"https://stock-news.laohu8.com/highlight/detail?id=2553225188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553225188?lang=en_us&edition=fundamental","pubTime":"2025-07-24 06:39","pubTimestamp":1753310392,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nTUEBBBZ2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2548868241","title":"Initial Director's Interest Notice-CHM.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548868241","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548868241?lang=en_us&edition=fundamental","pubTime":"2025-07-02 15:07","pubTimestamp":1751440048,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX7lvWJP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASXH1q0t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2548457260","title":"Professor Miles Prince appointed as Non-Executive Director-CHM.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548457260","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548457260?lang=en_us&edition=fundamental","pubTime":"2025-07-01 06:35","pubTimestamp":1751322906,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX9y1bZN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX1htdG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}